This is a corrigendum to a review article in The Lancet entitled "GLP-1 receptor agonists and next-generation incretin-based drugs: metabolic, cardiovascular and renal benefits", published in 2026 (407: 892–908). The authors are Michael A. Nauck, Katherine R. Tuttle, Matthias H. Tschöp and Matthias Blüher. Ludwig-Maximilians-Universität München (LMU Munich), Munich, Germany, is added to the affiliation of Matthias H. Tschöp. In the Declaration of Interests section, the information for Michael A. Nauck, Matthias H. Tschöp and Matthias Blüher has been corrected. The addendum was edited and the corrections were published in the online version on March 12, 2026.